SCHEMBL8765489

SCHEMBL8765489

NS(=O)(=O)c1ccc(-c2c(-c3ccc(F)cc3F)c(C(F)(F)F)nn2-c2ccccc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 19/20 0.61
PTGS1 P23219 15/20 0.61
PDPK1 O15530 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8765156 0.90 PTGS2 (0.48) PTGS2PTGS1
SCHEMBL8765753 0.90 PTGS2 (0.65) PTGS2PTGS1PDPK1
SCHEMBL8765055 0.88 PTGS2 (0.48) PTGS2PTGS1
SCHEMBL8635532 0.87 PTGS2 (0.68) PTGS2PTGS1PDPK1
SCHEMBL8631360 0.84 PTGS2 (0.73) PTGS2PTGS1PDPK1
SCHEMBL8765176 0.84 PTGS2 (0.51) PTGS2PTGS1PDPK1
SCHEMBL8764637 0.84 PTGS2 (0.72) PTGS2PTGS1PDPK1
SCHEMBL8765194 0.83 PTGS2 (0.61) PTGS2PTGS1PDPK1
SCHEMBL8764737 0.82 PTGS2 (0.61) PTGS2PTGS1PDPK1
SCHEMBL8609145 0.82 PTGS2 (0.65) PTGS2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0731794-B1 1,4,5-TRIPHENYL PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION AND INFLAMMATION-RELATED DISORDERS SEARLE & CO (US) 1997-08-06 EP disclosed
US-5639777-A 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders G.D. SEARLE & CO. (US) 1997-06-17 US disclosed
EP-0731794-A1 1,4,5-TRIPHENYL PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION AND INFLAMMATION-RELATED DISORDERS SEARLE & CO (US) 1996-09-18 EP disclosed
WO-1995015317-A1 1,4,5-TRIPHENYL PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION AND INFLAMMATION-RELATED DISORDERS G.D. SEARLE & CO. (US) 1995-06-08 WO disclosed